Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
NCT01868061 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
- Lead sponsor
- Hoffmann-La Roche
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2013
- Completion date
- January 2, 2017
- Enrollment
- 1,068 (actual)
- Sites
- 232
Conditions
As the registry lists them; a condition with its own page is linked.